Health
CureVac’s Covid-19 vaccine induces immune response in study – Clinical Trials Arena
CureVac has reported that the ongoing Phase I study of its Covid-19 vaccine candidate CVnCoV showed that it was well-tolerated across all tested doses ranging from…
CureVac has reported that the ongoing Phase I study of its Covid-19 vaccine candidate CVnCoV showed that it was well-tolerated across all tested doses ranging from 2 to 12µg and induced strong binding and neutralising antibody responses.
The Phase I study is evaluating the safety, reactogenicity and immunogenicity of the investigational vaccine CVnCoV, an optimised, non-chemically modified mRNA that encodes the prefusion stabilised full-length spike protein of the SARS-CoV-2 virus.
Its mode of action…
-
Noosa News21 hours agoMega-team of heavy horses sets world record at Good Old Days Festival
-
Noosa News13 hours agoNRL grand final quick hits: Reece Walsh creates magic after avoiding sin bin as Broncos survive Hunt, Reynolds injuries to win premiership
-
General13 hours agoHow the internet reacted to Brisbane Broncos winning the NRL grand final
-
General23 hours agoHomicide Squad investigating ‘suspicious’ death of 84yo woman in Sydney suburb of Melonba